To determine the usefulness of both amplitude and threshold data from tone-burst cervical vestibular evoked myogenic potential (cVEMP) testing for the evaluation of superior canal dehiscence syndrome (SCDS). STUDY DESIGN: Case series with chart review. SUBJECTS AND METHODS: Sixty-seven patients underwent cVEMP testing. We correlated mean tone burst cVEMP amplitude and threshold data with temporal bone CT findings. Patients were excluded for Ménière's disease, middle ear disease, or otologic surgery. RESULTS: Superior canal dehiscence patients had higher mean cVEMP amplitudes (SCDS 173.8 V vs non-SCDS 69.7 V, P ϭ 0.031) and lower mean thresholds (SCDS 72.8 dB nHL vs non-SCDS 80.9 dB nHL) at 500 Hz. CONCLUSION: Patients with SCDS have larger amplitudes and lower thresholds on cVEMP testing at 500 Hz. This study supports the utility of tone burst cVEMPs for the evaluation of SCDS and is one of few large single-center studies to establish normative data. had the best sensitivity and specificity characteristics at a cut point of 72.5 dB nHL to detect SCDS.
C ervical vestibular evoked myogenic potentials (cVEMPs) are being used more frequently to evaluate the complex dizzy patient. Myogenic potentials were first measured at the inion and later were discovered to be vestibular in nature. 1 In 1971, Cody and Townsend localized the VEMP response to the saccule. 2, 3 Colebatch recorded myogenic potentials from the sternocleidomastoid muscle (SCM) during presentation of ipsilateral sound stimuli. 4 Responses were observed during SCM contraction and were characterized by a triphasic waveform with an initial inhibitory (p13 or P1) followed by an excitatory (n23 or N1) response. 4 The third phase of the waveform has been hypothesized to be cochlear in nature. 5 Today, the cVEMP test is used to assess the integrity of the saccule, inferior vestibular nerve, and central vestibular nuclei in humans. 6 Clinical uses for VEMP testing include: 1) providing objective data that can assist in side of lesion identification for patients suspected of saccular hydrops (absent VEMP or reduced amplitude seen on affected side), 7 2) complementing the use of ENG/VNG (which evaluates horizontal canal function) in the assessment of the complex dizzy patient, 5 3) evaluating inferior vestibular nerve function in patients with a vestibular schwannoma, 5 and 4) assessing a patient with a third window (TW) seen in superior canal dehiscence (SCD) 8 or large vestibular aqueduct. 9 First described by Minor in 1998, SCD is the absence of bone overlying the superior semicircular canal, which is referred to as superior canal dehiscence syndrome (SCDS) when the patient is symptomatic. 10 The bony defect associated with SCDS (or large vestibular aqueduct) creates a TW (in addition to the oval and round windows) that has been theorized to alter endolymph and perilymph flow, decreasing "inner ear" impedance, and resulting in vestibular and/or auditory symptoms. 9, 11 The anatomic diagnosis of SCD is made using high-resolution CT of the temporal bone, and ideally reformatted to the planes of Pöschl and Stenver relative to the superior semicircular canal to detect a small defect and avoid volume averaging artifacts (Fig 1) .
The incidence of symptomatic SCD, or SCDS, is unknown but temporal bone studies suggest that the incidence of anatomic SCD is 0.5 percent. 12 We propose that cVEMP testing in the setting of anatomic SCD is crucial before discussing treatment options with the affected patient. VEMP data can provide evidence of altered vestibular function that can help determine whether the anatomic anomaly (seen on CT) is an incidental finding or is associated with an alteration of inner ear physiology. Previous studies have shown that cVEMP testing in SCDS demonstrates large amplitudes and decreased thresholds in the ear ipsilateral to the dehiscence. 13 However, only a few studies have pro-vided normative tone burst cVEMP data to provide a basis for careful comparison with TW ears as confirmed on CT imaging. The primary aim of our study was to determine the usefulness of both amplitude and threshold data from tone burst cVEMP to confirm the diagnosis of SCDS. Our second aim was to establish normative amplitude and threshold cVEMP data in non-TW ears. Our hypothesis is that ears with symptomatic SCD (SCDS) will have large amplitudes and lower thresholds to tone burst cVEMP testing compared with non-SCDS ears (including ears with anatomic dehiscence but no symptoms).
METHODS
This study was approved by the University of Massachusetts Medical School Human Subjects Committee. We conducted a retrospective review of the medical and audiologic records of patients who received cVEMP testing at the University of Massachusetts Memorial Medical Center, a tertiary referral center. Only patients who received both cVEMP testing and high-resolution temporal bone CT imaging were included. Patients less than 18 years old or with a history of Ménière's disease, middle ear disease, or otologic surgery were excluded.
Patient data included basic demographic information, presenting signs and symptoms, past medical history, audiometric testing, cVEMP amplitude and thresholds, and radiographic imaging. Standard audiologic testing was conducted in a sound-treated booth. Pure-tone audiometry was performed from 250 Hz to 8000 Hz for air conduction thresholds, and from 250 Hz to 4000 Hz for bone conduction thresholds. When applicable, bone conduction testing was administered with stimulus levels less than 0 dB HL (Ϫ5 and Ϫ10 dB HL) to detect conductive hyperacusis, a common feature in patients with SCDS. Appropriate masking was used when necessary. Tympanograms, distortionproduct otoacoustic emissions, and ipsilateral acoustic reflexes were also recorded for all patients included in our study.
cVEMPs
Cervical vestibular evoked myogenic potentials were evoked from each ear using air-conducted brief tone-burst stimuli presented through ER-3A insert earphones (Etymotic Research, Inc, Elk Grove Village, IL). Tone bursts were Blackman-gated with two cycles on the rise and fall with no plateau and center frequencies of 250, 500, and 1000 Hz. The stimulus rate was 8.1 bursts/second for amplitude measurements and 13.1 bursts/second for threshold measurements. An initial stimulus intensity of 95 dB nHL (117 pSPL) was used for the amplitude measurement. This was then decreased in 10-dB steps until no response was present and replicable, then increased by a final 5-dB step. If no response was present at the initial 95 dB nHL level, the stimulus was increased up to the limits of the transducer (110 dB nHL) as necessary.
Disposable silver/silver chloride surface electrodes were placed at the middle third of each SCM muscle (noninverting), each sternoclavicular notch (inverting), and the forehead (ground). The electromyogram (EMG) was bandpass filtered from 10 to 750 Hz. Patients were seated and reclined approximately 60 degrees with no head support, and were asked to rotate their head away from the side of the stimulus as far as was comfortable when the auditory stimulus was present. EMG activity was monitored with an oscilloscope to ensure that peak contraction levels exceeding 100 V were maintained for each recording. Between 100 and 500 sweeps were signal averaged to resolve each response.
Radiology
Patients included in this study underwent a high-resolution multidetector CT of the temporal bones. Radiology was performed at the Massachusetts Eye and Ear Infirmary with reformatting of images to Pöschl (parallel to plane of the superior canal) and Stenver (perpendicular) projections (Fig 1) .
Statistical Analysis
For all subjects, mean cVEMP thresholds (at 250 Hz, 500 Hz, and 1000 Hz), amplitudes (at 95 dB nHL and 500 Hz), and P1 latencies (at 500 Hz) were measured in both ears. Amplitude was measured as the peak-to-peak difference between the P1 and N1 waveforms. In order to compare amplitudes between SCD and non-SCD patients the ear with the largest amplitude was included in analysis for all patients. Similarly, latency comparisons were made including only the larger latency ear. To analyze thresholds, the lowest threshold for all ears was included. This ensured that the choice of the included ear was the same for both SCD and non-SCD patients.
The distributional characteristics of the outcomes were evaluated using both Kolmogorov-Smirnov goodness of fit test and visual inspection of frequency histograms both performed on residuals from the group means. The Student t test was used for amplitude transformation by natural logarithms resulting in normally distributed residuals and for differences between groups. For threshold and latency data the Mann-Whitney U test was used to evaluate differences as model residuals were not normally distributed.
The predictive ability of each measure was evaluated using the area under the receiver operating characteristics curves (AUCROC). Significant AUCROC cut points for defining categories were developed under the assumptions of equal prevalence and equal consequences for misclassification using the maximum of the product of sensitivity and specificity. For all statistical analyses, P Ͻ 0.05 was considered significant.
RESULTS
Sixty-six adult patients (36 female, 30 male) received cVEMP testing from 2005 to 2008. Thirteen patients had signs, symptoms, and radiology consistent with SCDS: nine with unilateral SCDS and four with bilateral SCDS. In total, 17 SCDS ears were compared with 107 non-SCDS ears.
Presenting symptoms in our subjects with SCDS included: aural fullness, hearing loss, dizziness/vertigo, and autophony. Among the patients in our cohort with a confirmed radiographic diagnosis of SCD, eight presented with aural fullness, seven with dizziness or vertigo, five with hearing loss, and three with autophony.
The mean cVEMP amplitude at 500 Hz, measured at 95 dB nHL, was 173.8 V (SD ϭ 324.9) for the SCDS group compared with 69.7 V (SD ϭ 98.0) for the non-SCDS group (Fig 2) . There was a statistically significant difference in mean amplitudes between these two groups (P ϭ 0.031). Latency measurements were also performed. The median P1 latency at 500 Hz in the SCDS group was 16.4 ms, and the non-SCDS group had a median P1 latency of 16.8 ms, but these differences were not statistically significant (P ϭ 0.735).
Threshold data are shown in Table 1 . Mean cVEMP thresholds for SCDS ears were 69.3 dB nHL (250 Hz) and 72.8 dB nHL (500 Hz) compared with non-SCDS ears (79.6 and 80.9 dB nHL, respectively). Median cVEMP thresholds at 250 Hz and 500 Hz were 70 and 80 dB nHL for SCDS ears. For non-SCDS patients, the mean thresholds were 80 and 80 dB nHL, respectively, at the same frequencies. At 250 and 500 Hz, there was a significant difference between the mean thresholds of the two groups (P ϭ 0.002 and P ϭ 0.041, respectively). However, at 1000 Hz, the difference between the two groups was not statistically significant (P ϭ 0.493).
Three patients in our cohort had anatomic evidence of SCD, but did not have signs or symptoms consistent with a TW. A total of five ears with asymptomatic SCD were seen. The mean cVEMP amplitude for this group at 500 Hz and measured at 95 dB nHL was 33.0 V (SD ϭ 17.9). The mean cVEMP thresholds for this group were 86, 87, and 93 dB nHL at 250 Hz, 500 Hz, and 1000 Hz, respectively (SD ϭ 4.7, 4.3, 2.4).
Figure 2
Mean amplitudes for the non-SCDS group and SCDS group at 500 Hz (measured at 95 dB nHL). Receiver operating characteristics curves (AUCROC) were created for all measures. The only significant AUCROC was for cVEMP thresholds at 250 Hz (AUCROC 0.764, P ϭ 0.026), revealing optimal sensitivity and specificity characteristics with a cut point of 72.5 dB nHL (sensitivity 67%, specificity 81%).
DISCUSSION
Our study demonstrates that threshold data at 250 Hz from tone-burst cVEMP testing are sensitive measures of symptomatic ears in patients with superior canal dehiscence, as a cut point of 72.5 dB nHL has a sensitivity of 67 percent and a specificity of 81 percent. SCDS ears exhibited higher amplitudes and lower thresholds compared with non-SCDS ears (amplitude at 500 Hz, P ϭ 0.031; threshold at 250 Hz, P ϭ 0.002, at 500 Hz, P ϭ 0.041). However, there was overlap in both amplitude and threshold data when the standard deviation was included in the analysis (Fig 2,  Table 1 ). Future studies that include a larger number of SCDS patients will be helpful to determine the sensitivity and specificity of cVEMPs in the evaluation of the TW.
For patients with radiographic evidence of SCD who lack classic signs and symptoms, cVEMP testing can help determine whether a bony dehiscence seen on temporal bone CT imaging affects inner ear physiology. In our cohort, examination of five asymptomatic ears with radiographically proven SCD showed mean cVEMP amplitudes and thresholds similar to the remaining non-SCDS ears with no evidence of radiographic dehiscence. The large amplitude difference between this asymptomatic group and that of the entire SCD cohort supports our hypothesis that the cVEMP may be a stronger clinical indicator of physiologic disturbance than radiologic findings. The decreased mean amplitude noted in the asymptomatic patients compared to the non-SCD patients was likely due to variability within this group and the small sample size.
cVEMPs therefore play a crucial role in patient counseling to provide evidence that a symptomatic ear is likely due to SCD and not secondary to another otologic condition. Although vestibular and, in some cases, auditory symptoms can be improved with surgery, a middle fossa craniotomy or transmastoid plugging is associated with risks (such as sensorineural hearing loss). 14, 15 We do not offer surgery to plug a symptomatic SCD unless the signs, symptoms, audiogram, cVEMPs, and radiology support the diagnosis. For patients with bilateral SCDS, cVEMPs may provide a way to determine the more symptomatic ear based on differences in amplitude or threshold if the clinical signs and symptoms appear similar between ears. The size of the dehiscence may not necessarily correlate with symptoms; however, studies that use a human SCD model suggest that the size of the dehiscence may correlate with the degree of conductive hearing loss. 16 Rajan et al demonstrated that lower-threshold acoustic stimuli produced a vestibular response in pa-tients with larger superior canal dehiscences. 17 In our experience, however, patients with large dehiscences do not always have vestibular symptoms. Radiology alone, especially in cases where the clinical signs and symptoms may be equivocal, may be insufficient in determining the ear with SCDS (as opposed to anatomic SCD) or the "worse ear" in patients with bilateral dehiscences. For this reason, we believe that cVEMP testing is an important complementary test to CT imaging of the temporal bone.
There are limitations to current cVEMP testing methods. Patients with severe Tullio's phenomenon or chronic cervical spine problems with limited range of motion may have difficulty completing the testing. In addition, VEMP responses typically decrease with age. 5 Recently, ocular VEMP testing (oVEMP) has been described. 18 oVEMPs are evoked EMG responses to loud sound and vibration. Unlike the inhibitory potentials that are measured in cVEMPs, however, oVEMPs are excitatory potentials recorded from the periocular muscles. Preliminary studies suggest that oVEMPs have less overlap of the standard deviations of amplitude and threshold data between SCDS and non-SCDS groups and may therefore be a more specific test for a symptomatic SCD. 14 However, reference ranges for control subjects have yet to be determined. 14 Finally, the cVEMP may be an important test if appropriate CT imaging is not available or multiplanar reconstruction is not performed. The established standard to confirm the presence of anatomic SCD is high-resolution temporal bone CT imaging with reconstructions in the planes parallel and perpendicular to the superior canal. 19 This approach is not yet widely performed and ears that on conventional temporal bone CT are suggestive of dehiscence (low-lying and/or dehiscent tegmen, SCD on coronal images) can be further evaluated for amplitude and threshold changes on cVEMP testing prior to any final management decision making. cVEMPs in experienced hands can be completed in fewer than 30 minutes and may be a more accessible method in the screening of patients with signs and symptoms suggestive of a TW (and no history of otologic surgery, middle ear disease, or Ménière's).
CONCLUSIONS
Tone-burst cVEMP amplitude and threshold data are sensitive measures of symptomatic superior canal dehiscence (SCDS). Patients with SCDS have larger cVEMP amplitudes and decreased thresholds compared with non-SCDS ears. SCDS ears had mean cVEMP amplitudes of 173.8 V (at 95 dB nHL) and mean cVEMP thresholds of 72.8 dB nHL at 500 Hz. Non-SCDS ears had lower mean cVEMP amplitudes of 69.7 V (at 95 dB nHL) and higher mean thresholds of 80.9 dB nHL at 500 Hz. Low-frequency (250 and 500 Hz) tone-burst cVEMPs are more sensitive than higher-frequency (1000 Hz) cVEMPs to detect symptomatic SCD. Based on ROC analysis cVEMP thresholds at 250 Hz
